MyHealthChecked PLC
("MyHealthChecked" or the "Company")
Notice of Results
MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, will announce its preliminary results for the year ended 31 December 2022 on Monday 3 April 2023.
Investor presentation
Penny McCormick, Chief Executive Officer and Nicholas Edwards, Chief Financial Officer will provide a live presentation relating to the preliminary results via the Investor Meet Company platform on Monday 3 April at 4.30pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9:00am BST the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet MyHealthChecked PLC via:
https://www.investormeetcompany.com/myhealthchecked-plc/register-investor
Investors who already follow MyHealthChecked Plc on the Investor Meet Company platform will automatically be invited.
For further information contact:
| MyHealthChecked PLC | ||
| Penny McCormick, Chief Executive Officer | via Walbrook PR | |
| | | |
| SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 | |
| Neil Baldwin | | |
| | | |
| Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 | |
| David Poutney / Nicholas Chambers | | |
| | | |
| Walbrook PR Ltd (Media & IR) | Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests that have been developed following the acquisition of The Genome Store in November 2020. The tests are available online, and in some cases, for over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
